Castle Biosciences reported results for 2026 with revenue of $103.55M, up from $86.19M a year earlier, while net loss was ($2.06M) versus net income of $4.52M in the prior year and diluted EPS was ($0.07) compared with $0.15— according to the company's 10-Q filing.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$103.55M$86.19M20.1% | Net income²($2.06M)$4.52M(145.5%) | Diluted EPS³($0.07)$0.15(146.7%) |
¹ Reported as “Net Revenues”. ² Reported as “Net (loss) income”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven by expansion into non-dermatologic tests; TissueCypher contributed meaningfully as the company shifted channels, with non-dermatologic tests representing roughly 52% of revenue.
- Test report volumes rose about 13% year to date; TissueCypher volumes increased approximately 61% YTD while DecisionDx‑Melanoma volumes were up about 9% YTD.
- AdvanceAD‑Tx limited launch (November 2025) recorded roughly 1,650 orders YTD, indicating early clinician interest.
- Operational investments included a Pittsburgh lab expansion and completion of the Friendswood headquarters, increasing TissueCypher capacity to meet demand.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.